Minocycline-induced hyperpigmentation in leprosy
- PMID: 8733393
Minocycline-induced hyperpigmentation in leprosy
Abstract
A 36-year-old man was treated with dapsone, rifampicin and clofazimine for borderline lepromatous leprosy. After 9 months, his leprosy plaques became progressively more red and after 23 months, the clofazimine was stopped and he was given minocycline instead. Six weeks later, he developed blue-black pigmentation in his leprosy lesions. The histology was consistent with minocycline-induced hyperpigmentation. This is the first report of minocycline-induced pigmentation in leprosy. We suggest it is important to consider this side-effect before the administration of minocycline in leprosy, particularly if it is prescribed in place of clofazimine.
Similar articles
-
Persistent serpentine supravenous hyperpigmented eruption in lepromatous leprosy after minocycline.Lepr Rev. 2015 Jun;86(2):191-4. Lepr Rev. 2015. PMID: 26502692
-
Minocycline-induced hyperpigmentation in multibacillary leprosy.Am J Dermatopathol. 2012 Dec;34(8):e114-8. doi: 10.1097/DAD.0b013e3182605052. Am J Dermatopathol. 2012. PMID: 23169418
-
Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy.J Drugs Dermatol. 2007 Dec;6(12):1232-6. J Drugs Dermatol. 2007. PMID: 18189065
-
Minocycline-induced skin pigmentation: an update.Acta Dermatovenerol Croat. 2009;17(2):123-6. Acta Dermatovenerol Croat. 2009. PMID: 19595269 Review.
-
Dermacase. Minocycline-induced pigmentation.Can Fam Physician. 2006 May;52(5):595-6. Can Fam Physician. 2006. PMID: 16739831 Free PMC article. Review. No abstract available.
Cited by
-
Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States.Ther Adv Infect Dis. 2022 Nov 8;9:20499361221135885. doi: 10.1177/20499361221135885. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 36387060 Free PMC article.
-
Minocycline-induced pigmentation. Incidence, prevention and management.Drug Saf. 1998 Jun;18(6):431-40. doi: 10.2165/00002018-199818060-00004. Drug Saf. 1998. PMID: 9638388 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical